Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.53.
During the past 3 years, the average EBIT per Share Growth Rate was 2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Boule Diagnostics AB's EBIT per Share or its related term are showing as below:
OSTO:BOUL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -22.7 Med: 11.2 Max: 47.2
Current: 2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Boule Diagnostics AB was 47.20% per year. The lowest was -22.70% per year. And the median was 11.20% per year.
OSTO:BOUL's 3-Year EBIT Growth Rate is ranked worse than 60.32% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs OSTO:BOUL: 2.00
Boule Diagnostics AB (OSTO:BOUL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Boule Diagnostics AB EBIT per Share Related Terms
Boule Diagnostics AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (OSTO:BOUL) has a EBIT per Share of kr0.53 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Boule Diagnostics AB and its competitors. According to the industry distribution chart, Boule Diagnostics AB ranks #415 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 60.3%.
Is Boule Diagnostics AB's EBIT per Share too high?
Boule Diagnostics AB's current EBIT per Share is kr0.53. Based on the distribution chart, Boule Diagnostics AB ranks #415 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #415 out of 688 companies for EBIT per Share. This places Boule Diagnostics AB in the lower half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EBIT per Share is kr0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Boule Diagnostics AB (OSTO:BOUL) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.14, compared to a current price of kr3.80 — trading 46.8% below its estimated fair value. The current EBIT per Share is kr0.53. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Boule Diagnostics AB (OSTO:BOUL), the current EBIT per Share is kr0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (OSTO:BOUL) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr3.80 is trading 46.8% below its estimated GF Value™ of kr7.14.
GuruFocus considers Boule Diagnostics AB to be Possible Value Trap.
Key valuation signals for OSTO:BOUL:
EBIT per Share: kr0.53
GF Value™: kr7.14 vs. price of kr3.80 (46.8% below fair value)
No single metric tells the full story. See the OSTO:BOUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for OSTO:BOUL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BOUL has been successfully added to your 
